Mitsubishi Gas Chemical Company has signed a strategic partnership agreement with Alerje, a Detroit-based health tech company providing an emergency medicine and food allergy management platform, to innovate allergy care.

MGC has set “medical/ food” as a target area in its medium-term management plan Grow UP 2026and is promoting a variety of related initiatives. These efforts come under the umbrella of MGC’S Key Issue (Materiality) “promotion of innovative R&D” which is part of Strategy 2 (Build new value through innovation) in Objective 1 (Strengthen the resiliency of our business portfolio) of the plan.

In connection with initiatives related to the development of food allergy diagnostic chips, MGC is building a model for predicting the severity of symptoms as well as establishing manufacturing system to provide kits for clinical research, with the aim of commercializing the chips as an in vitro diagnostic in the future.

Alerje is building a business around epinephrine auto-injectors and AI-enabled digital health tools. Their remote patient monitoring platform revolutionizes food allergy immunotherapy management through advanced data analytics. It not only gathers and processes vital information but also predicts treatment outcomes, enhancing care strategies for allergists.

With the signing of this basic agreement, MGC and Alerje will jointly explore optimal food allergy care solutions by combining our respective technologies to significantly improve patient treatment outcomes and quality of life.